Anelixis Therapeutics
Advancing impactful treatments to help patients combat the progression of neurodegenerative diseases.
Advancing impactful treatments to help patients combat the progression of neurodegenerative diseases.
Anelixis Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company specializing in the development of clinical-stage therapies focused on immune modulatory drugs for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and Alzheimer's Disease (AD). Founded in 2012, the company is dedicated to advancing impactful treatments that help patients combat the progression of their conditions. Their slogan, "Advancing impactful treatments to help patients combat the progression of neurodegenerative diseases," reflects their commitment to making a difference in the lives of patients. Anelixis Therapeutics secured a notable $2.57M Venture Round investment on 25 April 2018. The company's mission and focused approach in the biotechnology sector make it an intriguing prospect for venture capitalists seeking opportunities in the healthcare and biopharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.57M | - | 25 Apr 2018 | |
| Venture Round | $4.29M | - | 20 Jun 2017 |
No recent news or press coverage available for Anelixis Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
